Previous 10 | Next 10 |
2023-10-25 14:02:09 ET More on NovoCure NovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade) NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth HC Wainwright cuts NovoC...
2023-10-18 10:31:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The third quarter was ...
Highlights include a new analysis showing that Tumor Treating Fields therapy, when added to standard systemic therapies, did not adversely affect patients’ quality of life in the phase 3 LUNAR clinical trial. Novocure (NASDAQ: NVCR) today announced its participation in the Eu...
Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the thr...
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTField...
2023-09-19 10:15:00 ET Young medical companies with new therapies often navigate a challenging path. That's true today for NovoCure (NASDAQ: NVCR) , which makes a wearable device for treating cancer. The average investor might see NovoCure as yet another struggling cancer therapy co...
Presentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancer Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Ca...
2023-09-06 14:27:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regard...
2023-09-04 09:30:00 ET After its stock fell 31% on Aug. 28, leaving it down by 72% in the last 12 months, NovoCure (NASDAQ: NVCR) shareholders are bound to be quite displeased. The cancer-treating device maker remains unprofitable despite having its Optune portable therapy machine a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...